Progyny Sees Record Selling Season Pace with 1.2M New Covered Lives
Event summary
- Progyny's selling season is pacing to a record level, with commitments expected to add 1.2 million new covered lives in the first half of 2027.
- Employers are increasingly turning to Progyny's solutions to manage rising medical cost trends while expanding family-building services.
- Progyny's solutions have demonstrated a proven track record of delivering savings, total cost management, and ROI.
- The company's innovative program has shown consistent ability to increase the effectiveness of fertility treatment while lowering the risk of costly complications.
The big picture
Progyny's record selling season reflects a broader trend of employers seeking cost-effective solutions to manage rising medical expenses while expanding family-building services. The company's ability to deliver savings through superior clinical outcomes and effective total cost management positions it favorably in a market grappling with escalating healthcare costs. This strategic advantage could drive further adoption of Progyny's solutions among data-intensive employers.
What we're watching
- Market Demand
- How sustained demand for Progyny's solutions will affect its growth trajectory in 2027.
- Cost Management
- Whether Progyny can maintain its cost-saving benefits amid broader medical cost inflation.
- Execution Risk
- The pace at which Progyny can implement its solutions for the anticipated new covered lives.